



CODEN [USA]: IAJPBB

ISSN : 2349-7750

**INDO AMERICAN JOURNAL OF  
PHARMACEUTICAL SCIENCES**

SJIF Impact Factor: 7.187

Available online at: <http://www.iajps.com>

Research Article

**INFLUENCES OF DOMPERIDONE IN INCORPORATION  
WITH ANTACID IN TREATMENT OF LONG-LASTING  
SURFACE INDIGESTION**<sup>1</sup>Dr. Farheen Nisha, <sup>2</sup>Dr Manzoor Hussain, <sup>3</sup>Dr Madiha Hafeez<sup>1</sup>Allied Hospital Faisalabad, <sup>2</sup>Registrar, Medical A unit, MTI/Mardan Medical Complex,<sup>3</sup>Mardan University Medical and Dental College.

Article Received: November 2020 Accepted: December 2020 Published: January 2021

**Abstract:**

**Objective:** This investigation work intended to regulate the impressions of domperidone with mixture of antacid while handling the long-lasting surface indigestion.

**Methodology:** Total 94 victims who were suffering from long-lasting surface indigestion and obtained treatment from Sir Ganga Ram Hospital, Lahore from February 2017 to February 2018 were the members of this exploration work. We separated the victims into control and test group with forty-eight victims in each group with the operation of the dual blind process. We preserved the victims of regulator group by antacid, whereas we treated the victims of test group by domperidone in partnership with the antacid. We studied and experiential the scientific influences of the victims of both groups.

**Results:** The indications scores were not dissimilar among the victims of both groups before the conduct. We saw the expansion of suggestions scores in the victims of test group superior as compared to the victims of control group after handling ( $P < 0.050$ ). We experiment the general answer degree in the victims of check group as 97.920% (47 out of total 48) which was much higher as compared to the victims in control group (75%). After whole treatment, the overhaul impression of the stomach mucosa and reappearance rate after surgical interference in the victims of check group was much high as associated to those current in the group of panels ( $P < 0.050$ ).

**Conclusion:** Domperidone in collaboration with antacid can attain ideal impacts in the therapy of chronic superficial gastritis. This is much important for the treatment and early prognosis of the victims.

**Keywords:** long-lasting surface indigestion, methodology, prognosis, antacid, therapy, control.

**Corresponding author:****Dr. Farheen Nisha,**

Allied Hospital Faisalabad,

QR code



Please cite this article in press Farheen Nisha et al, **Influences Of Domperidone In Incorporation With Antacid In Treatment Of Long-Lasting Surface Indigestion.**, Indo Am. J. P. Sci, 2021; 08(1).

**INTRODUCTION:**

Epidemiological examination showed that there is very prevalence rate of long-lasting surface indigestion among all the gastrointestinal complications, which was from 51.70% to 85.44% that of the chronic gastritis; the rate of prevalence enhanced with the rise of age; it might grow to the atrophic gastritis if the treatment of this issue does not carry out timely [1, 2]. Long-lasting surface indigestion is very common gastritis disease of digestive system with high rate of incidence. Its induction normally caused by the chronic inflammatory abrasions resulted under the recurring actions of pathogenic features like microorganism, bile regurgitation and drugs on the gastric mucosa epithelium. Symptoms related to this complication like bloating, dyspepsia, belching, stomachache, emesis and nausea can produce the serious influences on the living quality and the physical health [3-5]. An investigation works accessible that from 50% to 80% victims who developed the difficulty of long-lasting surface indigestion always had the infection due to helicobacter pylori [6]. Now a days, the handling of the long-lasting surface heartburn with the antacid is very mutual treatment in medicinal field. Antacid reacting as proton pump inhibitor can create discerning impact on the wall cells of gastric mucosa, professionally inhibit the cylindrical effervesce inside the cytoplasm and movement of the enzyme's emission by the stomach wall lockups and finally it restrict the secretion of the gastric acid; but the impact of this treatment in no quite effective [7, 8]. A current investigation work presented that grouping of antacid with the domperidone was very capable in the conduct of long-lasting surface heartburn victims but this conclusion is not clear yet [9]. This exploration accepted out to crisscross the efficiency of the syndicate handling of antacid and domperidone for long-lasting surface heartburn victims.

**METHODOLOGY:**

Total 96 victims anguish from long-lasting surface heartburn who got handling in Jinnah Hospital, Lahore from February 2017 to February 2018 with complete analytical average were the part of this exploration work. We identified all the victims with compulsive variations and gastroscopic inspection. We detached the victims into check and regulator group with forty eight members in each group. In the group of controls, there were thirty male and eighteen female victims

with a mean age of  $42.82 \pm 2.72$  years and the average course of disease was  $1.25 \pm 0.25$ . In test group, twenty-seven were female and twenty-one male victims with a mean age of  $42.70 \pm 2.60$  years and mean course of disease among them was  $1.40 \pm 0.40$  years.


Victims suffering from other serious complications were not the part of this research work. We treated the victims of test group with antacid and domperidone. We administered the domperidone orally in a dose of ten milligrams every time thirty minutes before every meal time and we also administered antacid in a dose of twenty milligram every time two time daily in fasting state of victims. We regarded the 3 weeks as single course. There was no remarkable difference in both groups regarding sex, course of disease and age ( $P > 0.050$ ). We gave the victims of control group antacid orally twenty milligram every time 2 times in fasting state of victims. All the victims were present with the disorders of digestive system and dyspepsia. We took the written consent from all the victims after describing them the rationale of this research work. We restrict all the victims to leave all drugs before fourteen days of this test. We also compared the response rate of the victims of both groups. We also continued this treatment for three weeks. We followed up and tested victims every week in accordance with procedure. We also recorded the scores of symptoms and analyzed them. We determined the scores from 1 to 3 points as mild symptoms, medium from 4 to 7 points and severe from 8 to 10 points. We present the numerical information in percentage. P value of less than 0.050 was the significant one. We considered the treatment effective if there was no increase in symptoms. SPSS V. 22 was in use for the statistical analysis of the collected information. We expressed the measurement information in averages and standard deviations.

**RESULTS:**

The symptoms scores as pain, burning sensation, swelling and sour regurgitation in the upper abdomen displayed a remarkable improvement in the victims of test group as compared to the victims of control group ( $P < 0.050$ ) (Table-1). There was no remarkable difference in the symptoms scores between the victims of both groups before the start of treatment ( $P > 0.050$ ).

**Table-I: Comparison of symptom scores of the two groups before and after treatment.**

Group	Swelling pain		Burning sensation		Sour regurgitation	
	Before	After	Before	After	Before	After
Control group	6.300 ± 1.600	2.80 ± 0.700	5.40 ± 1.800	3.20 ± 1.300	7.20 ± 1.300	2.40 ± 0.500
Test group	6.10 ± 1.50	0.80 ± 0.30	5.60 ± 1.60	0.90 ± 0.40	7.60 ± 1.400	0.600 ± 0.30




After the complete therapy, scores of chronic and active inflammation of the victims of test group were very high as compared to the victims of group of controls with an obvious disparity ( $P < 0.050$ ) (Table-2), showing better repair of gastric mucosa in the test group as compared to the group of controls. The effectivity rate in the victims of test group and controls group was 97.920% & 75.0% correspondingly, and we found a significant disparity among both groups ( $P < 0.050$ ). During the course of treatment, symptoms of deficiency in strength & dizziness in appeared in 2

victims of control group (4.18%) but there was no adverse reaction in the test group. This finding showed that, the treatment of the test group was more effective as compared to the group of controls. We followed up the victims in both groups for complete 6 months. There was recurrence in one patient of test and 9 victims of control group (2.07% vs 18.76%). This finding was also present with statistically significant difference ( $P < 0.050$ ). The prevalence rate of the poor reactions between 2 groups displayed no significant difference statistically ( $P > 0.050$ ).

**Table-II: Comparison of gastric mucosa repair between the two groups after treatment.**

Group	No	Score of chronic inflammation	Score of active inflammation
t	-	4.8720	5.2730
P	-	<0. 0500	<0. 0500
Test group	48	1.020 ± 0.130	1.030 ± 0.220
Control group	48	1.630 ± 0.440	1.680 ± 0.370



### DISCUSSION:

There is very significant role of the impact of gastric acid in the prevalence of the LONG-LASTING SURFACE INDIGESTION. Antiacid has the ability to decrease the enzymes activity like APT, H<sup>+</sup> & K<sup>+</sup>, prevent the release of the gastric acid as well as inhibit the bacterial infection. Antiacid normally restricts the proton pump's activity to inhibit the release of gastric acid [11]. The symptoms of LONG-LASTING SURFACE INDIGESTION normally recur after the treatment. Toxin, drugs, microorganism and bile regurgitation are the main pathogenic features of LONG-LASTING SURFACE INDIGESTION. It is very difficult to identify these pathogenic factors accurately which makes the diagnosis of LONG-LASTING SURFACE INDIGESTION very hard [12]. Therefore, it is very frequent in use for the treatment of the CG. One research work stated that LONG-LASTING SURFACE INDIGESTION treatment can be carried out by antacid but the impact of this drug is not remarkable [13]. In the procedure of inhibition of the secretion of gastric acid, it can decrease the evacuation of drugs, promote the utilization rate of drug and efficiently relieve the victims from symptoms. It has its extensive application in treatment field of chronic gastritis. Additionally, antacid in combination with urease to prevent the activity of urease and finish Hp by entering into mucous layer & surface of Hp [14]. Domperidone also has the ability to promote the power of the digestion tract [15]. The findings of this research work showed that twelve victims out of forty-eight victims of group of controls gave no response to the therapy with the utilization of antacid, with a rate of efficacy of 75.0% which is similar to that finding. Domperidone has the ability to

inhibit the emesis. It has no ability to create adverse impacts on CNS (Central Nervous System). It has the ability to selectively block the dopamine-2 and have reaction on PNS (Peripheral Nervous System) [16]. There is very extensive application of the domperidone with much safety. All the findings of this research work showed that this combines treatment has very effective impacts.

### CONCLUSION:

It increases the curing rate and relieves the victims from symptoms of disease. It can be regarded as the significant procedure for the treatment of LONG-LASTING SURFACE INDIGESTION victims in medical field. The findings of this research work showed that the combination of antacid and domperidone in the treatment of LONG-LASTING SURFACE INDIGESTION is much effective and secure.

### REFERENCES:

1. Toller IM, Hitzler I, Sayi A, Mueller A. Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model. *Gastroenterology*. 2010; 138(4):1455-1467. doi: 10.1053/j.gastro.2009.12.006.
2. Deng WL. Observation of curative effects of antacid in treating 53 cases of chronic superficial gastritis. *J Med Theory Pract*. 2010;23(3):301-302.
3. Peng YC, Huang LR, Shyu CL, Cheng CC, Ho SP. Interaction of antacid and Helicobacter pylori-induced nuclear factor-κB activation and mediators in gastric epithelial cells. *J Chin Med*

- Assoc. 2014;77(11):567-572. doi: 10.1016/j.jcma.2014.07.006
4. Kihara M. Pepsin-like protease activity and the gastric digestion within ex vivo Pacific bluefin tuna *Thunnus orientalis* stomachs, as a gastric digestion model. *Animal Feed Sci Technol.* 2015;206: 87-99.
  5. Wu JC, Long EW, Chen ZY. Comparison of effectiveness of antacid and teprenone in treatment of chronic superficial gastritis. *Sichuan Med J.* 2014;3:331-333.
  6. Fan XT. Comparison of effects of antacid triplex methods in eliminating helicobacter pylori infection. *Chin J Mod Drug Appl.* 2011;5(1):134. doi: 10.3969/j.issn.1673- 9523.2011.01.124
  7. Wang HB. Comparison of effects of proton pump inhibitors and ranitidine in the treatment of dodecadactylon ball headquarter ulcer. *China Pract Med.* 2012;35:158-159.
  8. Ortiz A, Cooper CJ, Alvarez A, Gomez Y, Sarosiek I, McCallum RW. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. *Am J Med Sci.* 2015;349(5):421-424. doi:10.1097/MAJ.0000000000000439
  9. Ngoenmak T, Treepongkaruna S, Buddharaksa Y, Khositseth A. Effects of domperidone on QT interval in children with gastroesophageal reflux disease. *Pediatr Neonatol.* 2016;57(1):60-64. doi: 10.1016/j.pedneo.2015.03.015.
  10. Zhao ZT, Li Y, Zhang XL. Fourteen cases of chronic gastritis with stomach cold treated by long snake moxibustion on dog days. *World J Acupunct - Moxibust.* 2014;24(3):57-60. doi: 10.1016/S1003-5257(15)60014-9
  11. Qin F, Liu JY, Yuan JH. Chaihu-Shugan-San, an oriental herbal preparation, for the treatment of chronic gastritis: A meta-analysis of randomized controlled trials. *J Ethnopharmacol.* 2013;146(2):433-439. doi: 10.1016/j.jep.2013.01.029.
  12. Hassan TMM, Al-Najjar SI, Al-Zahrani IH, Alanazi FIB, Alotibi MG. Helicobacter pylori chronic gastritis updated Sydney grading in relation to endoscopic findings and H. pylori IgG antibody: diagnostic methods. *J Microsc Ultrastruct.* 2016;4(4):167-174. doi: 10.1016/j.jmau.2016.03.004
  13. Rodríguez C, Medici M, Rodríguez AV, Mozzi F, Font de Valdez G. Prevention of chronic gastritis by fermented milks made with exopolysaccharide-producing *Streptococcus thermophilus* strains. *J Dairy Sci.* 2009;92(6):2423-2434. doi: 10.3168/jds.2008-1724.
  14. Qiao CF. The observation of effect of domperidone in combination with antacid in the treatment of chronic superficial gastritis. *Chin Foreign Med Res.* 2013;11(26):41- 42. doi: 10.3969/j.issn.1674-6805.2013.26.029
  15. Ding Y. Observation of curative effect of antacid in combination with domperidone in the treatment of chronic superficial gastritis. *Chin J Clin Rational Drug Use.* 2010;03(11):46-47.
  16. Gao W, Li HY, Wang LX, Hao LJ, Gao JL, Zheng RJ, et al. Protective effect of antacid on gastric mucosal of cirrhotic portal hypertension rats. *Asian Pacific J Tropic Med.* 2014;7(5):402-406. doi: 10.1016/S1995-7645(14)60065-1.